D&D Pharmatech Granted Fast Track Designation from US FDA for DD01 for the Treatment of NASH/MASH
GYEONGGI-DO, South Korea & GAITHERSBURG, Md.--(BUSINESS WIRE)--D&D Pharmatech, Inc. (D&D), a clinical-stage biotechnology company focused on the development of disease-modifying drugs, today announced positive topline results from its Phase 1 clinical trial of DD01 in overweight/obese patients with type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD). DD01 is a long-lasting, dual GLP-1/glucagon receptor agonist designed to rapidly resolve hepatic steatosis, improve glycemic control, and reduce body weight in fatty liver disease with and without co-occurring T2D and obesity.
A Parkinson’s disease treatment from Neuraly, a biotech spun out from the Johns Hopkins School of Medicine, did not improve motor experiences of daily living or movement in a mid-stage trial, but the investigators did flag a better result for younger patients.